Potential OPDIVO® (nivolumab) user laughing in the kitchen with her husband.

Your fight against head and neck cancer may continue here

OPDIVO® (nivolumab) is an FDA-approved immunotherapy given by infusion for previously treated head and neck squamous cell carcinoma. OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy) is a faster option given by injection.*

Learn more about OPDIVO Qvantig

Actor portrayals.

*A 3-5 minute injection time of OPDIVO Qvantig compared to 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
OPDIVO Qvantig is not indicated for pediatric patients.

Previously treated squamous cell cancer of the head and neck

OPDIVO is a treatment option for certain adults with squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread after previous treatment

OPDIVO Qvantig is a treatment option for certain adults with SCCHN that has returned or spread after previous treatment

 

See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.
Explore another way you may receive treatment

You and your healthcare provider may have a choice between under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig and intravenous (lV) infusions with OPDIVO

OPDIVO Qvantig cannot be used in combination with YERVOY. OPDIVO and OPDIVO Qvantig will not work for everyone. Individual results may vary.

Man exploring real patients stories of experiences with OPDIVO® (nivolumab) or other OPDIVO-based combinations.

Patient stories

Real patients share their experiences with OPDIVO and OPDIVO-based treatments

Frequently asked questions about treatment with OPDIVO® (nivolumab).

Have questions about treatment?

We have answers about getting treatment, monitoring, and more

Hands exploring cost information and financial help for OPDIVO® (nivolumab).

Cost information and financial help

Find information about cost and access to OPDIVO



466-US-2600093 04/26